ICER On Asthma Biologics: 50%-79% Price Discounts Needed To Meet Value Assessment Metrics
The independent value assessment organization’s draft assessment found that the prices for all five marketed biologics for severe asthma – Xolair, Nucala, Cinqair, Fasenra and Dupixent – far exceed standard cost-effectiveness thresholds.
You may also be interested in...
Novartis Targets Chronic Urticaria As Ligelizumab Enters Late-Stage Trials
Two Phase III studies, PEARL 1 and PEARL 2, will compare Novartis's candidate anti-IgE antibody with the previous generation anti-IgE MAb, Xolair, for the treatment of chronic spontaneous urticaria.
Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics
The US FDA cleared Sanofi/Regeneron's IL-4/IL-13 inhibitor for moderate-to-severe asthma in patients with an eosinophilic phenotype or with oral corticosteroid-dependent asthma, a broader label than AstraZeneca's Fasenra, GSK's Nucala and Teva's Cinqair.
CVS Launching Program To Exclude New Drugs Deemed Not Cost Effective
Program would use cost per QALY determinations by the Institute for Clinical and Economic Review.